Methylcobalamin Producers Poised to Face Increased Demand from Chinese Consumers : Ken Research REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit By the end of this decade, the Chinese population is projected to witness increased incidence of peripheral neuropathy. In China Methylcobalamin annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014 at a CAGR of 12.32%. Ken Research introduces latest publication titled, “Investigation Report on China Methylcobalamin Market, 2010-2019”, offers detailed insights into the changing trends within the Chinese pharmaceuticals industry. The focus is primarily on the increasing demand for drugs that can treat peripheral neuropathy such as Methylcobalamin. A detailed profile of Methylcobalamin including its sales position, market share and pricing in the Chinese market is also present in the investigative report. Furthermore, competitive landscape of major players operating and future outlook of Methylcobalamin in China has also been discussed in the report. The advent of technology and increasing globalization has changed globally the lifestyles of people living in different parts of the globe. Increasing work-pressure along with the need to have a certain standard of life is forcing people to work beyond. As a result, a large proportion of the working age group is suffering from problems associated with peripheral neuropathy. It is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. One of the popular drugs for treating peripheral neuropathy is Methylcobalamin, derivative of Vitamin B12. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue. The sales of Methylcobalamin in China have been increasing steadily during the past decade. In fact, by the end of 2020, the incidence of peripheral neuropathy amongst Chinese pharmaceutical industry is expected to grow manifolds resulting in a direct positive impact on the sales of Methylcobalamin. Historically, its annual sales value increased from less than CNY 200 million in 2005 to CNY 441 million in 2014, at a CAGR of 12.32%. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share. Global Peripheral Neuropathy Market The peripheral nervous system in a human body is responsible for connecting the brain with the rest of the body. Any malfunctioning in the peripheral nerves is terms as peripheral neuropathy and the etiology of this medical condition includes dietary deficiencies, diabetes, chronic kidney disease, alcohol abuse and any hereditary disease. The Center for Disease Control and Prevention in the US has stated that the growing number of obese and geriatric people is a cause for peripheral neuropathy. Some of the leading market players in global space include Eli Lilly and Co., Novartis AG, Cipla Laboratories, Abbott Laboratories and GloxoSimitKline. Some important drivers within the global peripheral neuropathy market include: Increasing work-life imbalance Large number or obese and geriatric people Increased incidence of diabetes Improper food habits leading to nutritional deficiencies Increasing number of alcohol abuse cases worldwide Key Topics Covered in the Report: Detailed explanation of concepts of Methylcobalamin Sales situation of Methylcobalamin in global market Market profile of Methylcobalamin in China Sales situation of Methylcobalamin in China Market share of major Methylcobalamin producers in China Profilers of leading players in Chinese Methylcobalamin market Future outlook for Methylcobalamin in China, 2015-2019 Forecast of market scale Forecast of competition pattern To know more on coverage, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/investigation-report-china-methylcobalamin-market/8492-91.html Related Reports: https://www.kenresearch.com/healthcare/pharmaceuticals/peripheral-neuropathy-sensory-neuropathy-pipeline/8850-91.html https://www.kenresearch.com/healthcare/pharmaceuticals/peripheral-neuropathy-sensory-neuropathy-pipeline/10234-91.html Contact: Ken Research Ankur Gupta, Head Marketing & Communications query@kenresearch.com +91-124-4230204 Tags: China Methylcobalamin drugs Future Outlook, China Methylcobalamin Drugs Market Research Report, China Methylcobalamin Drugs Market size, Chinese pharmaceutical market, Future outlook of Methylcobalamin in China, Market Share of Methylcobalamin, Mecobalamin Introduction in China, Metabolic Disease China, NCPC Market Share in China Methylcobalamin, Peripheral Neuropathy Methylcobalamin, Sales price of Methylcobalamin, Therapeutic Drug of Peripheral Neuropathy
